海南海药(000566) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥293,077,257.52, a decrease of 28.36% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥34,092,369.05, representing a 29.63% increase in losses year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥54,117,396.69, a decrease of 27.44% compared to the previous year[5]. - Total operating revenue for the current period is ¥1,252,651,828.58, a decrease of 15.0% from ¥1,474,222,452.43 in the previous period[25]. - Net profit for the current period is -¥39,388,820.44, compared to -¥49,809,751.72 in the previous period, showing an improvement of 20.0%[26]. Cash Flow - The operating cash flow net amount for the year-to-date was ¥12,457,178.90, down 89.82% from the previous year[5]. - Net cash flow from operating activities dropped by 89.82% to CNY 12,457,178.90, mainly due to extended settlement periods and reduced tax refunds[10]. - Cash flow from operating activities generated a net amount of ¥12,457,178.90, a significant decrease from ¥122,311,458.09 in the previous period[28]. - The net cash flow from investing activities was CNY -72,523,551.54, a significant decrease compared to CNY 176,280,287.72 in the previous year[10]. - The net cash flow from financing activities improved by 83.95% to CNY -99,694,026.67, primarily due to reduced repayments of borrowings[10]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,296,321,662.90, a decrease of 0.94% from the end of the previous year[5]. - The company's cash and cash equivalents decreased by 40.87% to ¥233,300,040.73 due to fixed asset and R&D investments[8]. - The company's current liabilities increased to CNY 3,627,038,505.67 from CNY 4,002,711,952.06 at the beginning of the year, indicating a significant rise in short-term obligations[23]. - The total non-current liabilities rose to CNY 1,375,365,615.44, compared to CNY 1,025,553,677.52 at the start of the year, reflecting an increase in long-term financial commitments[23]. Inventory and Receivables - Inventory increased by 41.91% to ¥393,218,354.56, attributed to reasonable production reserves according to sales plans[8]. - The company reported a 97.15% increase in receivables financing to ¥47,594,591.31, mainly due to an increase in bank acceptance bills received[8]. - The accounts receivable increased to CNY 350,934,633.24 from CNY 326,448,446.69, showing a growth in credit sales[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,365[11]. - The largest shareholder, Hainan Huadong Industrial, holds 22.89% of shares, totaling 296,989,889 shares, with 148,494,944 shares pledged[11]. Legal and Regulatory Issues - The company is currently involved in a legal dispute regarding a contract with Yancheng Fengkang Fund, which may impact future financial performance[19]. - The company has been under investigation by the China Securities Regulatory Commission for alleged information disclosure violations, which could affect its market reputation[20]. Other Financial Metrics - The company's weighted average return on net assets was -1.59%, a decrease of 0.70% compared to the previous year[5]. - Basic earnings per share for the current period is -0.0189, an improvement from -0.0520 in the previous period[26]. - The company recorded a significant increase in credit impairment losses to ¥68,681,199.06 from ¥9,089,213.52 in the previous period[25].